Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

NCT ID: NCT04505436

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

215 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-31

Study Completion Date

2026-07-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NASH - Nonalcoholic Steatohepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HM15211

Group Type EXPERIMENTAL

HM15211

Intervention Type DRUG

A sterile solution of HM15211 (efocipegtrutide) contained in pre-filled syringes

Placebo

Group Type PLACEBO_COMPARATOR

Placebo of HM15211

Intervention Type DRUG

A sterile, matching solution in pre-filled syringes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HM15211

A sterile solution of HM15211 (efocipegtrutide) contained in pre-filled syringes

Intervention Type DRUG

Placebo of HM15211

A sterile, matching solution in pre-filled syringes

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

efocipegtrutide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* United States Sites: Adults ≥ 18 to ≤ 70 years.
* Korean Sites: Adults ≥ 19 to ≤ 70 years.
* BMI ≥ 18 kg/m2, with stable body weight (defined as change \< 5%) by history for 3 months prior to screening or since baseline liver biopsy, whichever is earlier.
* Subjects have a diagnosis of non-cirrhotic NASH with liver fibrosis (Fibrosis stage F1-F3) confirmed by liver biopsy within 6 months of Day -7.
* MRI-PDFF performed at screening with ≥ 8% steatosis.

Exclusion Criteria

* Subjects with a history of active or chronic liver disease, including alcoholic liver disease, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, Wilson's disease, hemochromatosis, alpha-1 antitrypsin deficiency, human immunodeficiency virus (HIV).
* Any history of clinically significant chronic liver disease including esophageal varices, ascites, hepatic encephalopathy, splenomegaly, or any hospitalization for treatment of chronic liver disease; or Model for End Stage Liver Disease \>12.
* Recent (within 3 months of baseline biopsy) use of therapies associated with development of NAFLD (e.g., systemic corticosteroids, methotrexate, tamoxifen, aromatase inhibitors, amiodarone, or long-term use of tetracyclines).
* Type 1 diabetes subjects, or T2DM subjects on GLP-1 receptor agonist therapy, or other therapies not allowed for this study
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hanmi Pharmaceutical Company Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

North Alabama GI Research Center

Huntsville, Alabama, United States

Site Status

Synexus US - Chandler

Chandler, Arizona, United States

Site Status

Precision Research Institute, LLC. (PRI)

Chula Vista, California, United States

Site Status

Fresno Clinical Research Center

Fresno, California, United States

Site Status

NAFLD Research Center - Altman Clinical and Translational Research Institute

La Jolla, California, United States

Site Status

UC Davis Health System - Midtown Ambulatory Care Center

Sacramento, California, United States

Site Status

University of Florida College of Medicine

Gainesville, Florida, United States

Site Status

Schiff Center for Liver Diseases - University of Miami Leonard M. Miller School of Medicine(UMMSM)

Miami, Florida, United States

Site Status

San Marcus Research Clinic

Miami Lakes, Florida, United States

Site Status

Floridian Clinical Research, LLC

Miami Lakes, Florida, United States

Site Status

Ocala GI Research

Ocala, Florida, United States

Site Status

Synexus Clinical Research US, Inc. - Orlando

Orlando, Florida, United States

Site Status

Synexus Clinical Research US, Inc. - The Villages

The Villages, Florida, United States

Site Status

Synexus Clinical Research US, Inc

Chicago, Illinois, United States

Site Status

Gastroenterology Health Partners, PLLC - Southern Indiana

New Albany, Indiana, United States

Site Status

Kansas Medical Clinic PA (KMC) - Gastrointestinal Medical Plaza

Topeka, Kansas, United States

Site Status

Tandem Clinical Research, LLC

Marrero, Louisiana, United States

Site Status

University of Maryland Medical Center

Baltimore, Maryland, United States

Site Status

Mercy Medical Center - The Institute for Digestive Health and Liver Disease

Baltimore, Maryland, United States

Site Status

Brigham and Women's hospital

Boston, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

West Michigan Clinical Research Center

Wyoming, Michigan, United States

Site Status

Mayo Clinic Rochester

Rochester, Minnesota, United States

Site Status

Nevada Family Care & Wellness Center

Henderson, Nevada, United States

Site Status

Tandem Clinical Research, LLC

New York, New York, United States

Site Status

UNC Health Care System

Chapel Hill, North Carolina, United States

Site Status

Carolinas Center for Liver Disease, Carolinas HealthCare System/Atrium Health

Charlotte, North Carolina, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Lucas Research

Morehead City, North Carolina, United States

Site Status

Consultants for Clinical Research

Liberty Township, Ohio, United States

Site Status

University of Pittsburgh Medical Center (UPMC) - The Center for Liver Diseases

Pittsburgh, Pennsylvania, United States

Site Status

ClinSearch

Chattanooga, Tennessee, United States

Site Status

Texas Clinical Research Institute, LLC

Arlington, Texas, United States

Site Status

Texas Liver Institute (TLI) - Texas Metabolic Center

Austin, Texas, United States

Site Status

The Liver Institute at Methodist Dallas

Dallas, Texas, United States

Site Status

Dallas Diabetes and Endocrine Center

Dallas, Texas, United States

Site Status

Liver Center of Texas, PLLC

Dallas, Texas, United States

Site Status

Synexus Clinical Research US, Inc

Dallas, Texas, United States

Site Status

Digestive Health Associates of Texas, P.A. (DHAT)

Garland, Texas, United States

Site Status

Baylor College of Medicine - Advanced Liver Therapies

Houston, Texas, United States

Site Status

Centex Studies, Inc.

Houston, Texas, United States

Site Status

Pioneer Research Solutions Inc

Houston, Texas, United States

Site Status

American Research Corporation at the Texas Liver Institute

San Antonio, Texas, United States

Site Status

University of Utah Health Care - UUHC - Kidney & Liver Clinic

Salt Lake City, Utah, United States

Site Status

Bon Secours Liver Institute of Virginia - Newport News

Newport News, Virginia, United States

Site Status

Virginia Commonwealth University (VCU) Medical Center

Richmond, Virginia, United States

Site Status

University of Washington (UW) - Harborview Medical Center (HMC) - Hepatitis and Liver Clinic

Seattle, Washington, United States

Site Status

Liver Institute Northwest

Seattle, Washington, United States

Site Status

Korea University Ansan Hospital

Ansan, Gyeonggi-do, South Korea

Site Status

Soonchunhyang university bucheon hospital

Bucheon-si, Gyeonggi-do, South Korea

Site Status

Natinal health insurance service Ilsan hospital

Goyang-si, Gyeonggi-do, South Korea

Site Status

The Catholic University of Korea, St. Vincent Hospital

Suwon, Gyeonggi-do, South Korea

Site Status

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

Site Status

Seoul National University College of Medicine - Liver Research Institute

Seoul, Seoul, South Korea

Site Status

Severance Hospital

Seoul, Seoul, South Korea

Site Status

SMG-SNU Boramae Medical Center

Seoul, Seoul, South Korea

Site Status

EWHA Womans University Mokdong Hospital

Seoul, Seoul, South Korea

Site Status

Korea University Guro Hospital

Seoul, Seoul, South Korea

Site Status

Eunpyeong St. Mary Hospital

Seoul, , South Korea

Site Status

Hanyang University Seoul Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HM-TRIA-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.